Question 1

What is Pariceract?

Accepted Answer

Pariceract is a Other.

Question 2

How often does Pariceract appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Pariceract first tracked by Ergen?

Accepted Answer

First tracked on May 26, 2026.

Question 4

When was Pariceract last mentioned in news?

Accepted Answer

Last active on Jun 09, 2026.

Question 5

What is Pariceract's current news sentiment?

Accepted Answer

Aggregate sentiment score: -100 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Pariceract in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Pariceract?

Accepted Answer

Bial's BIA 28-6156 fails Parkinson's trial (May 26, 2026, 6 articles).

Question 8

How did the "Bial's BIA 28-6156 fails Parkinson's trial" event impact Pariceract?

Accepted Answer

Pariceract, a drug in development by Bial for GBA1-associated Parkinson s disease, failed to meet its primary and key secondary efficacy endpoints in the Phase 2b ACTIVATE study, leading to its discontinuation. This marks the end of its development for this indication.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.